Overview Dividends

(BNTX) BioNTech SE - Ratings and Ratios

Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US09075V1026

Oncology Vaccines,Checkpoint Antibodies,MRNA Therapies,Cellular Immunotherapies

BNTX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -38.26%
EPS Trend (3Y Correlation): -54.9%

BNTX Revenue

Revenue Growth (3Y CAGR): -31.38%
Revenue Trend (3Y Correlation): -26.8%

Risk via 10d forecast
Volatility	42.8%
Value at Risk 5%th	58.6%

Reward
Sharpe Ratio	0.11
Alpha	-22.02

Character
Hurst Exponent	0.277
Beta	1.308

Drawdowns 3y
Max DD	57.88%
Mean DD	41.01%

Description: BNTX BioNTech SE October 14, 2025

BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm focused on developing mRNA-based immunotherapies for cancer and infectious diseases. Its pipeline includes more than 20 candidates across all clinical phases, notably BNT111 (Phase 2 melanoma), BNT113 (Phase 2 head-and-neck squamous cell carcinoma), BNT116 (Phase 1 non-small cell lung cancer), and the multi-indication BNT122/RO7198457 (Phase 2 adjuvant urothelial carcinoma, colorectal, pancreatic and advanced melanoma). The company also advances late-stage assets such as BNT311/GEN1046 (Phase 3 solid tumors) and BNT327 (spanning Phase 1-3 trials for small-cell lung cancer, TNBC, neuroendocrine neoplasms, and hepatocellular carcinoma).

Key recent metrics: as of Q2 2024, BioNTech reported €2.9 billion in revenue, driven primarily by its COVID-19 vaccine partnership with Pfizer, while cash and equivalents stood at €4.1 billion, providing a runway of over three years at current burn rates. The mRNA platform’s scalability and the broader biotech sector’s 12-month forward-looking P/E median of ~30× underscore both high growth potential and valuation pressure. A material driver of future earnings is the ability to leverage the existing mRNA manufacturing network for oncology candidates, which could reduce cost-of-goods-sold (COGS) by up to 20 % relative to early-stage trials.

For a deeper quantitative assessment, the ValueRay platform offers a granular view of BNTX’s risk-adjusted upside.

BNTX Stock Overview

Market Cap in USD	24,801m
Sub-Industry	Biotechnology
IPO / Inception	2019-10-10
Return 12m vs S&P 500	-16.1%
Analyst Rating	4.38 of 5

BNTX Dividends

Currently no dividends paid

BNTX Growth Ratios

CAGR	-13.26%
CAGR/Max DD Calmar Ratio	-0.23
CAGR/Mean DD Pain Ratio	-0.32
Current Volume	607.9k
Average Volume	534.7k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-571.6m TTM) > 0 and > 6% of Revenue (6% = 189.2m TTM)

FCFTA -0.05 (>2.0%) and ΔFCFTA -9.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 431.7% (prev 525.1%; Δ -93.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.01 (>3.0%) and CFO -316.8m > Net Income -571.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 7.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (239.2m) change vs 12m ago -2.21% (target <= -2.0% for YES)

Gross Margin 82.49% (prev 84.31%; Δ -1.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 14.41% (prev 13.57%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -31.47 (EBITDA TTM -161.4m / Interest Expense TTM 17.3m) >= 6 (WARN >= 3)

Altman Z'' 13.58

(A) 0.64 = (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b

(B) 0.86 = Retained Earnings (Balance) 18.27b / Total Assets 21.34b

warn (B) unusual magnitude: 0.86 — check mapping/units

(D) 6.45 = Book Value of Equity 18.49b / Total Liabilities 2.86b

Total Rating: 13.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 15.74

1. Piotroski 1.0pt = -4.0

2. FCF Yield -15.23% = -5.0

3. FCF Margin -34.64% = -7.50

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda 61.01 = -2.50

6. ROIC - WACC (= -22.57)% = -12.50

7. RoE -3.04% = -0.51

8. Rev. Trend -26.77% = -2.01

9. EPS Trend -54.92% = -2.75

What is the price of BNTX shares?

As of November 11, 2025, the stock is trading at USD 105.07 with a total of 607,901 shares traded.
Over the past week, the price has changed by +1.07%, over one month by +2.95%, over three months by -3.83% and over the past year by -3.37%.

Is BioNTech SE a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, BioNTech SE (NASDAQ:BNTX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 15.74 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BNTX is around 86.31 USD . This means that BNTX is currently overvalued and has a potential downside of -17.85%.

Is BNTX a buy, sell or hold?

BioNTech SE has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy BNTX.

Strong Buy: 13
Buy: 3
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BNTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	134.8	28.3%
Analysts Target Price	134.8	28.3%
ValueRay Target Price	98.1	-6.6%

BNTX Fundamental Data Overview November 10, 2025

Market Cap EUR = 21.45b (24.80b USD * 0.865 USD.EUR)
P/E Forward = 7.0373
P/S = 7.867
P/B = 1.157
P/EG = 0.0449
Beta = 1.308
Revenue TTM = 3.15b EUR
EBIT TTM = -544.8m EUR
EBITDA TTM = -161.4m EUR
Long Term Debt = 214.7m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 53.4m EUR (from shortTermDebt, last quarter)
Debt = 245.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 7.17b EUR (21.45b + Debt 245.4m - CCE 14.53b)
Interest Coverage Ratio = -31.47 (Ebit TTM -544.8m / Interest Expense TTM 17.3m)
FCF Yield = -15.23% (FCF TTM -1.09b / Enterprise Value 7.17b)
FCF Margin = -34.64% (FCF TTM -1.09b / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 82.49% ((Revenue TTM 3.15b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 90.24% (prev 70.71%)
Tobins Q-Ratio = 0.34 (Enterprise Value 7.17b / Total Assets 21.34b)
Interest Expense / Debt = 0.16% (Interest Expense 399.1k / Debt 245.4m)
Taxrate = 216.2% (out of range, set to none) (53.4m / 24.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = 61.01 (negative EBITDA) (Net Debt -9.85b / EBITDA -161.4m)
Debt / FCF = 9.02 (negative FCF - burning cash) (Net Debt -9.85b / FCF TTM -1.09b)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.68% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -2.86% (EBIT -544.8m / Capital Employed (Equity 18.83b + L.T.Debt 214.7m))
RoIC = -11.87% (negative operating profit) (EBIT -544.8m / (Assets 21.34b - Curr.Liab 2.22b - Cash 14.53b))
WACC = 10.71% (E(21.45b)/V(21.70b) * Re(10.83%) + (debt cost/tax rate unavailable))
Discount Rate = 10.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.38%
Fair Price DCF = unknown (Cash Flow -1.09b)
EPS Correlation: -54.92 | EPS CAGR: -38.26% | SUE: 0.77 | # QB: 0
Revenue Correlation: -26.77 | Revenue CAGR: -31.38% | SUE: 1.27 | # QB: 1

Additional Sources for BNTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle